GSK remains ‘very confident’ in RSV vaccine amid competition, sales slump

Com­pe­ti­tion is heat­ing up in the RSV space, de­spite a luke­warm quar­ter for vac­cine up­take.

Pfiz­er beat GSK’s Arexvy for the first time in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.